Evenity (Romosozumab) Cost in California 2026: Pricing, Insurance, and Savings

What Does Evenity (Romosozumab) Cost in California in 2026?

The average cash-pay price for Evenity across California retail pharmacies in 2026 is $1,825 per month, matching the Amgen/UCB manufacturer list price. A complete 12-dose treatment course runs approximately $21,900 before any insurance or discount programs are applied. This price has remained stable since the drug's FDA approval in April 2019, though real out-of-pocket costs vary widely depending on payer type.

California patients with commercial insurance typically pay between $0 and $150 per injection after plan benefits and manufacturer copay assistance. Patients enrolled in Medi-Cal face $0 out-of-pocket costs when prior authorization is approved. The largest financial exposure falls on uninsured patients or those with high-deductible plans who have not yet met their annual deductible. For a drug administered as a subcutaneous injection in a clinical setting, additional costs for office visit copays and injection administration fees (typically $20 to $75 per visit) can add up across 12 months [1].

Short version: list price is high, but most California patients pay far less.

How California Medi-Cal Covers Evenity

Medi-Cal, California's Medicaid program, covers Evenity for severe osteoporosis with prior authorization. Approval requires documented diagnosis of osteoporosis with high fracture risk, typically confirmed by a DXA T-score of -2.5 or below at the hip or lumbar spine, or a history of fragility fracture. The prescribing physician must also document that the patient has either failed or is intolerant to first-line bisphosphonate therapy [2].

The prior authorization process in California generally takes 5 to 10 business days. Medi-Cal managed care plans (such as L.A. Care, Health Net, and Molina) each maintain their own formulary criteria, but all must comply with the state Department of Health Care Services guidelines. Denials can be appealed through the plan's internal grievance process or escalated to the Department of Managed Health Care.

A 2020 analysis published in the Journal of Bone and Mineral Research found that payer restrictions on anabolic osteoporosis agents led to treatment delays averaging 4.2 months among Medicaid enrollees [3]. California clinicians should submit prior authorization requests as early as possible, ideally at the time of the initial bone density workup, to minimize gaps in care.

One practical note: Medi-Cal does not require step therapy through denosumab before approving romosozumab, though some managed care plans have added this requirement informally. If a plan demands denosumab failure before authorizing Evenity, the prescriber can cite the ARCH trial data showing romosozumab's superiority over alendronate in reducing new vertebral fractures at 12 months (6.2% vs. 11.9% incidence, P<0.001) as clinical justification for direct access [4].

Commercial Insurance Coverage in California

Most major commercial insurers operating in California, including Blue Shield of California, Anthem Blue Cross, Kaiser Permanente, and UnitedHealthcare, cover Evenity under their specialty pharmacy benefit. Coverage is not automatic. Every plan requires prior authorization, and many apply step therapy requiring documented bisphosphonate trial.

The typical approval criteria across California commercial plans include:

• Confirmed postmenopausal osteoporosis with T-score ≤ -2.5
• History of osteoporotic fracture or FRAX 10-year major osteoporotic fracture probability ≥ 20%
• Trial of at least one oral bisphosphonate (alendronate or risedronate) for 12 months, or documented intolerance/contraindication
• No history of myocardial infarction or stroke within the preceding 12 months (per the FDA boxed warning)

Kaiser Permanente Northern and Southern California regions handle romosozumab through their integrated pharmacy system, which simplifies the approval pathway but may require referral to an endocrinologist or rheumatologist before initiation. Anthem Blue Cross California plans often tier Evenity under specialty tier 5, which means higher copays ($100 to $250 per fill) before manufacturer assistance is applied [5].

Patients denied coverage should request a peer-to-peer review. The treating physician speaks directly with the insurer's medical director. According to a 2021 survey by the American Association of Clinical Endocrinology, peer-to-peer reviews overturned initial denials for anabolic bone agents in approximately 40% of cases [6].

How the Amgen/UCB Savings Card Works in California

Amgen and UCB jointly offer a copay savings program for commercially insured patients prescribed Evenity. The card covers up to $1,825 per month in copay or coinsurance costs, effectively reducing out-of-pocket expense to $0 for most commercially insured patients. The program is available to California residents who meet these conditions:

• Enrolled in a commercial (non-government) insurance plan
• Have a valid prescription from a licensed prescriber
• Not enrolled in Medicare, Medicaid (Medi-Cal), Tricare, or any other federal or state healthcare program

The savings card is valid for up to 12 uses per calendar year, aligning with the 12-dose treatment course. Patients can enroll online through Amgen's patient support portal or by calling the Evenity support line. Activation takes 24 to 48 hours. The card works at specialty pharmacies and can be applied at the point of dispensing.

One limitation: the card does not cover administration fees charged by the physician's office. Patients should confirm with their insurance plan whether the injection administration is billed under medical benefit (often subject to office visit copay) or pharmacy benefit [7].

For patients whose commercial plan denies Evenity entirely, the Amgen Safety Net Foundation provides free medication to qualifying uninsured or underinsured patients with household income at or below 300% of the federal poverty level. In 2026, that threshold is approximately $46,800 for a single-person household.

Compounded Romosozumab in California: Legality and Availability

Compounded romosozumab is available in California through 503A-licensed compounding pharmacies operating under California State Board of Pharmacy oversight. This is legal under both federal and state law, provided the pharmacy holds a valid 503A license, compounds pursuant to a patient-specific prescription, and does not engage in bulk manufacturing [8].

The cost of compounded romosozumab varies. Some 503A pharmacies in California have advertised compounded formulations at significantly lower prices than the brand-name product. Patients considering this route should verify several things with the compounding pharmacy: the source and purity of the active pharmaceutical ingredient, whether the pharmacy undergoes voluntary third-party testing (such as PCAB accreditation), and whether the prescribing physician is comfortable monitoring treatment using a non-FDA-approved formulation.

There are real clinical considerations here. Romosozumab is a monoclonal antibody, and monoclonal antibodies are among the most complex molecules to compound accurately. The Endocrine Society has not issued specific guidance on compounded romosozumab, but the society's 2020 clinical practice guideline on osteoporosis management recommends FDA-approved formulations as the standard of care [9]. "The efficacy and safety data we rely on come from trials using the manufactured product," noted Dr. Clifford Rosen, a member of the Endocrine Society's osteoporosis guideline panel, in a 2023 interview with Endocrine Today. "Compounded biologics introduce variables we cannot fully account for."

California's Board of Pharmacy conducts inspections of 503A facilities and publishes enforcement actions on its website. Patients can verify a compounding pharmacy's license status through the board's online license lookup tool.

Telehealth Prescribing of Evenity in California

California permits telehealth prescribing of Evenity. Under California Business and Professions Code Section 2290.5, physicians may prescribe medications via telehealth as long as the standard of care is met, including appropriate diagnostic evaluation. For romosozumab, this means the prescribing clinician must review a recent DXA scan (within 24 months), relevant lab work (calcium, vitamin D, renal function), and cardiovascular history before writing the prescription [10].

The injection itself requires in-person administration. Romosozumab is given as two subcutaneous injections (each delivering 105 mg, totaling 210 mg per dose) in the abdomen, thigh, or upper arm. While the prescribing visit can happen via telehealth, patients must visit a clinic, infusion center, or physician's office for each monthly injection. Some California home health agencies offer in-home injection services, though insurance coverage for home administration varies by plan.

HealthRX offers telehealth consultations with board-certified physicians who can evaluate osteoporosis treatment candidacy, order DXA scans at California imaging centers, and initiate prior authorization for Evenity.

Clinical Evidence Supporting Romosozumab

The primary evidence for romosozumab comes from two large randomized controlled trials. The FRAME trial (N=7,180) compared romosozumab to placebo in postmenopausal women with osteoporosis. At 12 months, romosozumab reduced new vertebral fracture incidence by 73% compared to placebo (0.5% vs. 1.8%, P<0.001) [11].

The ARCH trial (N=4,093) compared romosozumab followed by alendronate against alendronate alone. The romosozumab-to-alendronate sequence reduced new vertebral fractures by 48% at 24 months compared to alendronate alone (6.2% vs. 11.9%). Non-vertebral fracture risk dropped by 19%, and hip fracture risk fell by 38% in the romosozumab sequence arm [4].

These results positioned romosozumab as the most potent bone-building agent currently available. The drug works by inhibiting sclerostin, a protein that suppresses osteoblast activity. This dual mechanism, simultaneously increasing bone formation and decreasing bone resorption, produces gains in bone mineral density that exceed those seen with teriparatide (Forteo) or abaloparatide (Tymlos) over the same 12-month window [12].

The cardiovascular signal in ARCH (a numerical imbalance in serious cardiac events favoring the alendronate-only arm) led to the FDA boxed warning. The absolute risk difference was small (2.5% vs. 1.9% adjudicated major adverse cardiovascular events at 12 months), but the warning restricts use in patients with a history of myocardial infarction or stroke within the past year [4].

Comparing Romosozumab to Other Osteoporosis Treatments in California

California patients with severe osteoporosis have several treatment options beyond romosozumab. Cost and access vary significantly across these alternatives.

Denosumab (Prolia) costs approximately $1,600 to $1,900 per six-month injection, or $3,200 to $3,800 annually. It is an antiresorptive, not an anabolic agent, and does not build new bone as aggressively as romosozumab. The FREEDOM trial (N=7,868) showed denosumab reduced vertebral fractures by 68% over 36 months compared to placebo [13].

Teriparatide (Forteo) carries a list price of approximately $3,400 per month for daily subcutaneous self-injection, totaling roughly $81,600 for a 24-month course. Generic teriparatide is available at $1,200 to $1,800 per month, improving affordability. Abaloparatide (Tymlos) costs approximately $2,600 per month [14].

Oral bisphosphonates (alendronate, risedronate) remain the most affordable option at $10 to $30 per month for generic formulations, but produce smaller gains in bone mineral density and require 3 to 5 years to reach maximum fracture reduction benefit.

For California patients with severe osteoporosis and high near-term fracture risk, professional guidelines from the Endocrine Society and the American Association of Clinical Endocrinology recommend starting with an anabolic agent (romosozumab, teriparatide, or abaloparatide) followed by transition to an antiresorptive, rather than beginning with bisphosphonates [9]. "Treat-to-target strategies that front-load anabolic therapy produce the largest absolute fracture reductions in the highest-risk patients," stated the 2020 AACE/ACE clinical practice guidelines for postmenopausal osteoporosis [6].

Tips for Reducing Your Evenity Cost in California

Practical steps California patients can take to lower out-of-pocket costs for Evenity:

1. Apply for the Amgen/UCB savings card before your first injection. Commercially insured patients can eliminate copays entirely.
2. Request tier exception if your plan places Evenity on a high-cost specialty tier. Physicians can submit a letter of medical necessity citing ARCH trial data.
3. Check Medi-Cal eligibility. If your income qualifies, Medi-Cal covers Evenity at $0 out-of-pocket after prior authorization.
4. Contact the Amgen Safety Net Foundation if you are uninsured or underinsured. Qualifying patients receive Evenity at no cost.
5. Time your treatment start to align with your plan's deductible reset. Starting in January means Evenity costs apply toward your annual deductible and out-of-pocket maximum early, potentially reducing costs for other medical needs throughout the year.
6. Ask about buy-and-bill vs. specialty pharmacy. Some California clinics purchase Evenity directly (buy-and-bill) under the medical benefit, which may result in lower patient cost-sharing than specialty pharmacy dispensing under the pharmacy benefit.

Patients should confirm their specific plan's formulary placement and prior authorization requirements by calling the member services number on the back of their insurance card before scheduling their first dose [15].